Xiong Ting, Peng Huimin, Chen Guoxi, Yuan Ye
Department of Biochemistry & Molecular Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
J Huazhong Univ Sci Technolog Med Sci. 2008 Aug;28(4):375-8. doi: 10.1007/s11596-008-0401-5. Epub 2008 Aug 15.
To investigate the invasive ability of the residual tumor cells after immunotherapy and explore the feasible approach suppressing the invasion, mice were inoculated with B16 cells, and then treated by gene therapy with p4-1BBL/psPD-1 or IFN-gamma. The production and activities of MMP-9 and MMP-2 in residual tumor tissues were analyzed with gelatin zymography 1 day and 7 days after the termination of the immunotherapy. The production of MMP-9 and MMP-2 by B16 cells treated with IFN-gamma was also analyzed. IFN-gamma-treated B16 cells were inoculated to mice via subcutaneous injection. The invasion of tumor to muscular tissue was analyzed. Gene therapy with CH50 was used to suppress the invasive growth of tumor. The results showed that the expression and the activities of MMP-9 and MMP-2 were significantly increased 7 days after the end of immunotherapy. The response of tumor cells to ECM molecules was intensified after the removal of IFN-gamma, resulting in significant increase of both the production and activities of MMP-9 and MMP-2, and the increased invasion of tumor. Gene therapy with CH50 effectively suppressed the invasive growth of tumor. It is concluded that the termination of immunotherapy may result in a higher metastatic potential of residual tumor cells. Suppressing tumor invasion by suitable treatment will improve the efficacy of immunotherapy.
为研究免疫治疗后残留肿瘤细胞的侵袭能力,并探索抑制其侵袭的可行方法,将小鼠接种B16细胞,然后用p4-1BBL/psPD-1或干扰素-γ进行基因治疗。在免疫治疗结束后1天和7天,用明胶酶谱法分析残留肿瘤组织中基质金属蛋白酶-9(MMP-9)和基质金属蛋白酶-2(MMP-2)的产生及活性。还分析了经干扰素-γ处理的B16细胞中MMP-9和MMP-2的产生情况。将经干扰素-γ处理的B16细胞通过皮下注射接种到小鼠体内,分析肿瘤向肌肉组织的侵袭情况。用CH50进行基因治疗以抑制肿瘤的侵袭性生长。结果显示,免疫治疗结束7天后,MMP-9和MMP-2的表达及活性显著增加。去除干扰素-γ后,肿瘤细胞对细胞外基质分子的反应增强,导致MMP-9和MMP-2的产生及活性均显著增加,肿瘤侵袭性增强。用CH50进行基因治疗可有效抑制肿瘤的侵袭性生长。结论是,免疫治疗的终止可能导致残留肿瘤细胞具有更高的转移潜能。通过适当治疗抑制肿瘤侵袭将提高免疫治疗的疗效。